These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30341683)

  • 41. Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.
    Quercia R; Perno CF; Koteff J; Moore K; McCoig C; St Clair M; Kuritzkes D
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):125-135. PubMed ID: 29474268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elsulfavirine: First Global Approval.
    Al-Salama ZT
    Drugs; 2017 Oct; 77(16):1811-1816. PubMed ID: 28940154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
    AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A simple stability indicating RP-HPLC-DAD method for concurrent analysis of Tenofovir Disoproxil Fumarate, Doravirine and Lamivudine in pure blend and their combined film coated tablets.
    Godela R; Gummadi S
    Ann Pharm Fr; 2021 Nov; 79(6):640-651. PubMed ID: 34019910
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reverse transcriptase fidelity and HIV-1 variation.
    Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
    Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
    [No Abstract]   [Full Text] [Related]  

  • 48. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
    Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients.
    Soulie C; Santoro MM; Charpentier C; Storto A; Paraskevis D; Di Carlo D; Gennari W; Sterrantino G; Zazzi M; Perno CF; Calvez V; Descamps D; Ceccherini-Silberstein F; Marcelin AG
    J Antimicrob Chemother; 2019 Mar; 74(3):614-617. PubMed ID: 30476106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA notifications. Combination lamivudine and tenofovir tablet approved.
    AIDS Alert; 2010 Jan; 25(1):10. PubMed ID: 20140989
    [No Abstract]   [Full Text] [Related]  

  • 51. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
    Wang Y; De Clercq E; Li G
    Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):813-829. PubMed ID: 31556749
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
    Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K
    Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.
    Markowitz M; Grobler JA
    Curr Opin HIV AIDS; 2020 Jan; 15(1):27-32. PubMed ID: 31658118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection.
    Dubrocq G; Rakhmanina N
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):773-779. PubMed ID: 29985071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection.
    Dando TM; Scott LJ
    Drugs; 2005; 65(2):285-302. PubMed ID: 15631548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

  • 58. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cabotegravir Plus Rilpivirine: First Approval.
    Markham A
    Drugs; 2020 Jun; 80(9):915-922. PubMed ID: 32495274
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.